Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

2foods, a Plant-Based Food Brand Originated in Japan, and Kagome Team Up to Develop Plant-Based Eggs Made From Vegetables

Published

2 years ago

on

 

A plant-based food brand “2foods” by TWO Inc. (TWO) has joined forces with Kagome Co., Ltd. (Kagome), a Japanese food manufacturing giant known for its tomato ketchup and vegetable juices, to launch their first collaborative product “2foods Plant-Based Omurice” on March 9th, 2022. The new product is made from plant-based eggs called “Ever Egg”, a joint-development between the two companies.

Omurice is a popular Japanese comfort food — a chicken and vegetable fried rice flavored with ketchup and wrapped in an omelet, often served with demi-glace sauce or ketchup on top. It is an example of Western-influenced Japanese cuisine that has fans of all ages from all over the world.

TWO and Kagome co-developed “Ever Egg” using vegetables such as carrots and cannellini beans, also known as white kidney beans, as the main ingredient instead of the more commonly used soybeans. By implementing a proprietary technology called “the vegetable semi-ripening method” (patent pending), “Ever Egg” is able to achieve the soft, fluffy texture similar to omelets made from real eggs. The demi-glace sauce and the chicken fried rice in “2foods Plant-Based Omurice” are also made entirely plant-based.

“2foods Plant-Based Omurice” will be available for pre-order on “Makuake” starting March 9th, 2022. Makuake is Japan’s top product launch platform where consumers come to pre-order and support the newest and most innovative creations. It is frequently used even by the largest corporations to introduce their new products to the market.

Through Makuake, TWO and Kagome aim to lead, and accelerate, the growth of the plant-based foods market in Japan. “2foods Plant-Based Omurice” will be offered as part of the menu at all six 2foods cafe/restaurant locations, and will be made available across more channels before the end of the year. The two companies will continue to work together in bringing innovative plant-based products to consumers around the world.

  • Product Development

The Plant-Based Foods Market in Japan

In recent years, the global plant-based foods market has expanded significantly due to a growing interest in environmental sustainability as well as vegan and vegetarian lifestyles. Its global market size is estimated to reach 18 trillion yen[1] by 2030.

The Japanese market has almost quadrupled in the last ten years (it has grown 3.7 times its size since 2010)[2] on its own, driven mostly by the health benefits of eating low-fat, low-calorie foods. Today, more consumers are choosing to eat plant-based foods as a way of practicing ethical consumption.

2foods: a Plant-Based Food Brand

2foods was created under the concept of “healthy junk food.” Although plant-based foods have received considerable attention over the last years, as one of three basic human desires, “what we eat” must taste good in order for it to truly become part of our lives. 2foods’ goal is to reinvent the taste of junk food  — the kind of experience that stimulates all of our five senses — and provide a lineup of plant-based foods that are flavorful, yet healthy and ethical.

Business Alliance with Kagome

In April 2021, TWO, the company behind 2foods, agreed to form a business alliance with Kagome, a global manufacturer and distributor of condiments, foods, and beverages. Kagome boasts the highest market share in tomato ketchup, tomato juices, and fruit and vegetable mixed juice markets in Japan, and has a wide range of offerings from vegetable seeds to furniture and other everyday items.

Furthermore, in January 2022, Kagome invested in 2foods to strengthen the partnership between TWO and Kagome, and pursue product development that essentially promote a sustainable future and new lifestyles that incorporate plant-based foods.

“2foods Plant-Based Omurice” is the first of such collaboration.

  • Omurice with “Ever Egg”

“2foods Plant-Based Omurice” uses “Ever Egg,” plant-based egg product developed by TWO and Kagome. According to a report, dairy, meat, and eggs are expected to be the three major categories of alternative foods by 2030[3]. Unlike dairy and meat, there are still very few products in the market that use plant-based eggs despite its market potential, and “Ever Egg” goes one step further in taking on this challenge by using vegetables such as carrots and cannellini beans as the main ingredient.

When producing plant-based alternative proteins (e.g. meat, eggs), soybeans are often used as the core component; however, it is difficult to eliminate the distinct smell and the dry and crumbly texture of soybeans. To overcome this problem, TWO and Kagome co-developed “the vegetable semi-ripening method” (patent pending), which allows plant-based eggs based on this technology to be able to recreate the soft, fluffy texture that was not possible before.

1: Bloomberg Intelligence

2: TPC Marketing Research Corp.

3: Expert Market Research, Global Vegan Food Outlook

  • Product Details *Packed Frozen

Ever Egg (Plant-Based Egg)

After many trials and errors, “Ever Egg” was developed under “the vegetable semi-ripening method,” made from carrots, cannellini beans, and other vegetables to achieve the soft, fluffy texture of real eggs. A patent application has been filed for this zero-cholesterol product.

Plant-Based Chicken Fried Rice

“Plant-Based Chicken Rice” uses soy meat that has the meaty, fibrous texture and juiciness of real chicken. By marinating the soy meat with Kagome’s original recipe of vegetable-based seasoning and Worcestershire sauce, and cooking with super sweet corn, it achieves the perfect fried rice full of delicious aroma.

The following two types of sauces are available:

Plant-Based Demi-Glace Sauce

“Plant-Based Demi-Glace Sauce” is made with sauteed onions, red wine, soy butter, and vegetable-based seasoning to recreate the juiciness that comes from slow-cooked beef. Fried onion bits are added to enhance the aroma to further increase your appetite.

Plant-Based Tomato Ketchup

“Plant-Based Tomato Ketchup” takes advantage of Kagome’s specialty tomato puree, mixed with domestic cane sugar to bring out the sweetness of tomatoes. This ketchup containing sea salt made from Okinawa seawater makes a great companion to “2foods Plant-Based Omurice.”

*Please note that Ever Egg, Plant-Based Omurice, and the Sauces are all produced in a facility that makes other foods that may contain animal products, including meat (beef/pork), poultry, fish, eggs, and dairy products.

  • Pre-Order Information (Limited to 2,350 Sets)

Product Name: 2foods Plant-Based Omurice

Available Period: March 9, 2022 ~ April 20, 2022

URL: https://www.makuake.com/project/2foods_kagome_omelet-rice/

*Please note that this item is produced in a facility that makes other foods that may contain animal products, including meat (beef/pork), poultry, fish, eggs, and dairy products.

  • In Store

Available at all 2foods cafe/restaurant locations: https://2foods.jp/pages/store

  • About 2foods

2foods is a plant-based food brand from Japan. Under the concept of “healthy junk food”, 2foods has dedicated itself to creating food that is not only tasty, fragrant, and aesthetically pleasing, but also affordable and familiar – an idea we like to define as “yummy.” 2foods’ mission is to spread the culture of an ethical, plant-based eating that is kind to both our health and our environment. https://2foods.jp

  • About TWO, Inc.

TWO is a well-being company that refuses to believe in a trade-off between healthy eating and happy living. TWO designs products and services that are “truly satisfying,” so that they are good for our bodies, our hearts, and our communities.

*Company names, product names, and logos mentioned in the press release are registered trademarks or trademarks of the respective companies.

*Unauthorized copying and replication of the contents of this article, text and images are strictly prohibited.

SOURCE TWO Inc.

Related Topics:

Wladimir P. is a Content Editor at European Gaming Media and at PICANTE Media and covers a large variety of industries.

Continue Reading

Artificial Intelligence

Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times

Published

4 hours ago

on

May 21, 2024

By

ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times

Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.

“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and  economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html

Continue Reading

Artificial Intelligence

Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data

Published

4 hours ago

on

May 21, 2024

By

department-of-health-–-abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research,-clinical-trials,-and-real-world-data

ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.

 
 
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html

Continue Reading

Artificial Intelligence

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe

Published

4 hours ago

on

May 21, 2024

By

biopharma-leaders-shape-the-future-of-drug-development-at-veeva-r&d-and-quality-summit-europe

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending